Crossject
Develops emergency medications delivered via a needle-free auto-injector platform.
ALCJ | PA
Overview
Corporate Details
- ISIN(s):
- FR0004178614 (+6 more)
- LEI:
- 969500W1VTFNL2D85A65
- Country:
- France
- Address:
- 6 Rue Pauline Kergomard, 21000 dijon
- Website:
- https://www.crossject.com/en
- Sector:
- Manufacturing
Description
Crossject is a specialty pharmaceutical company focused on developing and commercializing medications for life-threatening emergency situations. The company's core technology is ZENEO®, a proprietary, pre-filled, single-use needle-free auto-injector. This platform is designed to enable patients or untrained caregivers to rapidly, safely, and reliably administer emergency treatments. Crossject's product pipeline targets critical conditions such as epileptic seizures, acute adrenal crisis, and severe allergic reactions (anaphylaxis), aiming to improve patient outcomes by simplifying drug delivery in urgent scenarios.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-06-04 19:30 |
Crossject announces highly successful closing of its €8 million rights offering
|
English | 221.4 KB | ||
| 2024-05-30 10:30 |
Crossject annonce la publication de données cliniques sur ZEPIZURE® dans Neurol…
|
French | 138.3 KB | ||
| 2024-05-30 10:30 |
Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and…
|
English | 197.9 KB | ||
| 2024-05-02 17:30 |
Crossject signe une extension géographique de l'accord de commercialisation de …
|
French | 180.2 KB | ||
| 2024-05-02 17:30 |
Crossject signs a geographic extension of ZEPIZURE® commercialization agreement…
|
English | 185.5 KB | ||
| 2024-04-30 19:05 |
Crossject annonce le lancement d’une augmentation de capital
|
French | 264.9 KB | ||
| 2024-04-25 07:32 |
Crossject communique ses résultats financiers audités pour 2023
|
French | 278.6 KB | ||
| 2024-04-25 07:32 |
Crossject reports audited financial results for 2023
|
English | 296.3 KB | ||
| 2024-04-10 16:30 |
Crossject : Information relative au nombre total de droits de vote et d'actions…
|
French | 194.8 KB | ||
| 2024-04-02 18:35 |
Crossject trading on Euronext to resume as usual on Wednesday April 3
|
English | 127.2 KB | ||
| 2024-04-02 18:35 |
La cotation sur l’action de Crossject à Euronext reprendra comme d’habitude le …
|
French | 119.5 KB | ||
| 2024-04-02 10:30 |
Crossject advances in its U.S. Strategy and reports Financial Results for 2023
|
English | 252.4 KB | ||
| 2024-04-02 10:30 |
Crossject poursuit sa stratégie de développement aux États-Unis et publie ses r…
|
French | 256.0 KB | ||
| 2024-03-08 07:30 |
Le Score de l’index Egalité femmes-hommes chez Crossject atteint 96/100 en 2024
|
French | 185.1 KB | ||
| 2024-03-08 07:30 |
Crossject gender equality score reaches 96/100 in 2024
|
English | 192.5 KB |
Automate Your Workflow. Get a real-time feed of all Crossject filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Crossject
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Crossject via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-06-24 | N/A | Other | Buy | 20,000 | N/A |
| 2024-06-14 | N/A | Other | Other | 10,979 | 20,289.19 EUR |
| 2024-06-06 | N/A | Other | Other | 1,058,617 | 1,956,324.22 EUR |
| 2024-06-06 | N/A | Other | Other | 16,106 | 29,763.89 EUR |
| 2024-06-06 | N/A | Other | Other | 10,275 | 18,988.20 EUR |
| 2024-06-06 | N/A | Other | Other | 10,074 | 18,616.75 EUR |
| 2024-06-06 | N/A | Other | Buy | 5,536 | 10,230.53 EUR |
| 2023-03-06 | N/A | Other | Other | 22,859 | 75,434.70 EUR |
Peer Companies
